


IV. Conclusion

All issues raised by the Office Action have been addressed. Reexamination, reconsideration and allowance of claims 7, 15-17 and 37-38 is requested.

Respectfully submitted,


Stephen Donovan
Registration Number 33,433

Date: February 20, 2003

Please direct all correspondence to

Stephen Donovan
Allergan, Inc.
2525 Dupont Drive, T2-7H
Irvine, CA 92612
Tel: 714 246 4026
Fax: 714 246 4249


CERTIFICATE OF EXPRESS MAIL UNDER 37 C.F.R. §1.10

I hereby certify that this Amended Response and the documents referred to as enclosed herein, are being deposited with the United States Postal Service on **February 20, 2003** in an envelope as "Express Mail Post Office To Addressee" mailing label number EL385561245US with sufficient postage for Express Mail addressed to Assistant Commissioner for Patents, Washington, DC 20231.

Date: February 20, 2003

Susan Bartholomew

Name of person mailing paper


Signature of person mailing paper

THE CLAIMS

E1 7. (Currently amended) A method for treating bradycardia, the method comprising the step of intrapericardial injection of a botulinum toxin to an the SA sinoatrial node or to an the AV atrioventricular node of a heart of a patient with bradycardia, thereby treating bradycardia.

15. (Previously amended) The method of claim 7, wherein the botulinum toxin is botulinum toxin type A and the amount of botulinum toxin type A locally administered to the heart is between about 0.01 U/kg and about 35 U/kg.

16. (Previously amended) The method of claim 7 wherein the botulinum toxin is botulinum toxin type A and the amount of botulinum toxin type A locally administered to the heart is between about 0.1 U/kg and about 30 U/kg.

17. (Previously amended) The method of claim 7, wherein the botulinum toxin is botulinum toxin A and the amount of botulinum toxin A locally administered to the heart is between about 1 U/kg and about 25 U/kg.

37. (Previously added) The method of claim 7, wherein the botulinum toxin is selected from the group consisting of botulinum toxins types A, B, C, D, E, F and G.

E2 38. (Currently amended) A method for treating bradycardia, the method comprising the step of intrapericardial injection of a botulinum toxin type A to an the SA sinoatrial node or to an the AV atrioventricular node of a heart of a patient with bradycardia, thereby treating bradycardia.